Objective: To assess levels of glial fibrillar acidic protein (GFAP), myelin basic protein (MBP), neurone-specific enolase (NSE) and S100B in patients with first-onset schizophrenia.
Method: We investigated CSF and serum samples from 12 patients with first-onset schizophrenia and from 17 control subjects by ELISA (GFAP, MBP) or immunoluminometric sandwich assays (NSE, S100B).
Results: Patients with schizophrenia had significantly higher levels of S100B in CSF (p = 0.004; 2.73 (SD 0.80) v 1.92 (0.58) μg/l) and serum (p = 0.032; 0.09 (0.03) v 0.08 (0.02) μg/l) in comparison with those in the matched control group. No diagnosis-dependent differences of protein concentration were seen for GFAP, MBP and NSE.
Discussion: Our finding of increased levels of S100B in patients with schizophrenia without an indication for significant glial (GFAP, MBP) or neuronal (NSE) damage may be interpreted as indirect evidence for increased active secretion of S100B during acute psychosis.
- ANOVA, analysis of variance
- CSF, cerebrospinal fluid
- GFAP, glial fibrillar acidic protein
- MBP, myelin basic protein
- NSE, neurone-specific enolase
- S100B, calcium-binding protein
Statistics from Altmetric.com
Competing interests: None.